Veraxa Biotech AG (VRXA)
VRXANASDAQ-GMBiotechnology: Pharmaceutical Preparations
$1.04
-0.0050 (-0.48%) today
At the close, Nov 17, 4:00 PM ET. After hours $1.02 -1.83%
- Market cap
- $147.06m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- $1.03 to $1.06
- 52-week range
- $0.9000 to $27.36
- Average volume
- –
- Previous close
- $1.05
News
7 latest- Biotech Stocks In Focus - SXTC +536% On Sharp Move; VRXA, AVBP, SPRC On Key Developments RTTNews · Oct 7, 2026
- VERAXA Biotech Adopts FDA-Aligned Models To Support Oncology Development RTTNews · Oct 7, 2026
- VERAXA Appoints Willener CFO As Pipeline Advances; Stock Up RTTNews · Sep 4, 2026
- VERAXA Biotech And Secarna Pharma Post Positive In Vitro Study Update In AOC Alliance RTTNews · Aug 24, 2026
- VERAXA Biotech AG Names Carl Von Halem As Interim Chief Financial Officer RTTNews · Jul 13, 2026
- Top Biotech Gainers: PPCB Launches Share Buyback, VRXA Partners With ATUM, SLS On Watch RTTNews · Jul 3, 2026
- Top Biotech Gainers: VRXA Begins A New Chapter, ADIL Opens Wallet, PGEN, PCSA On Watch... RTTNews · Jun 11, 2026
The company
At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- Europe
- Website
- veraxa.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.